Human epidermal growth factor receptor 2 (HER2)-negative, hormone receptor positive patients with early disease may have their risk profile determined by a range of clinicopathological risk factors including patient age, tumor size and grade, and lymph node (LN) involvement. Here, ERBB2 is linked to neoplasm.